Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UGM1

UPID:
ACHA9_HUMAN

ALTERNATIVE NAMES:
Nicotinic acetylcholine receptor subunit alpha-9

ALTERNATIVE UPACC:
Q9UGM1; Q14CY7; Q4W5A2; Q9NYV2

BACKGROUND:
Neuronal acetylcholine receptor subunit alpha-9, also known as Nicotinic acetylcholine receptor subunit alpha-9, is integral in the modulation of auditory stimuli. Its activation induces a conformational change, opening an ion-conducting channel across the plasma membrane, allowing the influx of divalent cations. This influx may activate a potassium current, leading to cell membrane hyperpolarization. Additionally, it plays a role in regulating keratinocyte adhesion, highlighting its multifunctional nature.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Neuronal acetylcholine receptor subunit alpha-9 offers a promising avenue for developing novel therapeutic strategies, especially for auditory system protection and skin health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.